logo
Twitter
Discord
Email
logo
ImmunityBio, Inc.

ImmunityBio, Inc.

NASDAQ•IBRX
CEO: Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-07-28
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Contact Information
3530 John Hopkins Court, San Diego, CA, 92121, United States
844-696-5235
immunitybio.com
Market Cap
$2.32B
P/E (TTM)
-6.4
42.1
Dividend Yield
--
52W High
$4.27
52W Low
$1.83
52W Range
22%
Rank63Top 84.3%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$32.06M+425.07%
4-Quarter Trend

EPS

-$0.07-49.29%
4-Quarter Trend

FCF

-$68.91M-32.15%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Product Revenue Surge Product revenue $74.710M YTD, showing 976% growth versus the prior nine-month period, driven by ANKTIVA sales.
Operational Loss Reduction Loss from operations $(191.344M)$ for nine months, representing an $83.438M improvement (30%) reduction versus 2024.
Cash Position Strengthening Cash and marketable securities totaled $257.8M as of September 30, 2025, increasing from $153.7M since June 30, 2025.
UK Market Entry MHRA granted UK marketing authorization for ANKTIVA in July 2025, marking the first international approval outside the U.S.

Risk Factors

Financing Needs Anticipates needing substantial additional financing to fund ongoing operations, commercialization, and future product development efforts.
Commercial Dependency Substantially dependent on successful ANKTIVA commercialization; limited commercial company experience presents execution risks.
Regulatory Hurdles Papillary NMIBC sBLA received FDA RTF letter; evaluation for new randomized controlled trial path is ongoing.
Debt Covenants Impact RIPA obligations impose restrictive covenants that may adversely affect cash flow and limit flexibility to raise capital.

Outlook

Expand ANKTIVA Use Pursuing regulatory approvals for new indications including second-line GBM, NHL, and other oncology targets.
Increase Operating Expenses Expect operating expenses to increase substantially supporting commercialization build-out and R&D expansion across multiple platforms.
Future Capital Planning Will require additional financing soon; plans include potential equity offerings, strategic partnerships, or debt financing options.
Manufacturing Scale-Up Capital spending accelerating to scale GMP manufacturing capabilities, requiring significant future capital investment.

Peer Comparison

Revenue (TTM)

Travere Therapeutics, Inc.TVTX
$435.83M
+114.2%
Galapagos NVGLPG
$316.64M
-3298.7%
Adaptive Biotechnologies CorporationADPT
$252.75M
+42.6%

Gross Margin (Latest Quarter)

Galapagos NVGLPG
475.5%
+375.5pp
ImmunityBio, Inc.IBRX
99.4%
-0.6pp
Adaptive Biotechnologies CorporationADPT
69.4%
+20.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TVTX$3.12B-35.1-178.7%61.2%
IDYA$2.98B-9.1-31.4%2.6%
BEAM$2.78B-6.8-42.9%11.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
61.9%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 2, 2026
|
EPS:-$0.08
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $32.06M+425.1%
    |
    EPS: $-0.07-49.3%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $26.43M+2423.9%
    |
    EPS: $-0.10-50.0%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $16.52M+41192.5%
    |
    EPS: $-0.15-25.0%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|
    Revenue: $14.75M+2270.6%
    |
    EPS: $-0.59+48.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $6.11M+7346.3%
    |
    EPS: $-0.14-26.3%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 12, 2024|
    Revenue: $1.05M+2453.7%
    |
    EPS: $-0.20-37.5%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $40.00K-88.9%
    |
    EPS: $-0.20-42.9%
    Meet

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 19, 2024|
    Revenue: $622.00K+159.2%
    |
    EPS: $-1.15-10.6%
    Miss